A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

LESSONS LEARNED. Single‐agent selinexor has limited activity in heavily pretreated patients with metastatic triple‐negative breast cancer. Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side‐effect profile consistent with previous clinical trials. Future studies of selinex...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Shafique, Michael, Ismail‐Khan, Roohi, Extermann, Martine, Sullivan, Dan, Goodridge, Dawn, Boulware, David, Hogue, Deanna, Soliman, Hatem, Khong, Hung, Han, Hyo S.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656474/
https://ncbi.nlm.nih.gov/pubmed/30996012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0231
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars